Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma
Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...
NHC Issues Notification on Medication Safety Management and Rational Drug Use
The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and...
Ningbo Health Gene Raises Hundreds of Millions in Series C Financing
Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised...
Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun...
Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures
Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...
Intellective Biologics Raises Over RMB500m in Series C Financing Round
China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly...
MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...
invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19
invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...
Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...
BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...
Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...
CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...
Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...
Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...